Total Payments
$440,992
2024 Payments
$70,161
Companies
46
Transactions
1,150
Medicare Patients
3,674
Medicare Billing
$920,006
Payment Breakdown by Category
Other$370,148 (83.9%)
Travel$34,465 (7.8%)
Food & Beverage$23,232 (5.3%)
Consulting$12,407 (2.8%)
Education$698.27 (0.2%)
Gifts$42.36 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $318,077 | 150 | 72.1% |
| Honoraria | $52,072 | 26 | 11.8% |
| Travel and Lodging | $34,465 | 182 | 7.8% |
| Food and Beverage | $23,232 | 751 | 5.3% |
| Consulting Fee | $12,407 | 13 | 2.8% |
| Education | $698.27 | 26 | 0.2% |
| Gift | $42.36 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $79,630 | 188 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $78,938 | 115 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $60,693 | 80 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $58,940 | 105 | $0 (2024) |
| Horizon Therapeutics plc | $55,470 | 101 | $0 (2023) |
| Amgen Inc. | $27,512 | 65 | $0 (2024) |
| Keryx Biopharmaceuticals, Inc. | $22,927 | 44 | $0 (2018) |
| Relypsa, Inc. | $19,408 | 54 | $0 (2020) |
| Otsuka America Pharmaceutical, Inc. | $16,349 | 89 | $0 (2024) |
| Horizon Pharma plc | $5,030 | 10 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $70,161 | 171 | Amgen Inc. ($27,174) |
| 2023 | $79,921 | 190 | Horizon Therapeutics plc ($27,540) |
| 2022 | $77,027 | 196 | Bayer HealthCare Pharmaceuticals Inc. ($26,015) |
| 2021 | $44,217 | 112 | Mallinckrodt Hospital Products Inc. ($22,209) |
| 2020 | $15,489 | 66 | AstraZeneca Pharmaceuticals LP ($6,718) |
| 2019 | $59,633 | 146 | Mallinckrodt Enterprises LLC ($40,358) |
| 2018 | $58,976 | 136 | Mallinckrodt LLC ($26,209) |
| 2017 | $35,568 | 133 | Mallinckrodt LLC ($12,370) |
All Payment Transactions
1,150 individual payment records from CMS Open Payments — Page 1 of 46
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,520.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: NEPHROLOGY | ||||||
| 12/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $26.03 | General |
| Category: Cardio-renal | ||||||
| 12/10/2024 | Vifor Pharma, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Hyperkalemia | ||||||
| 12/09/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,312.50 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/09/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $18.24 | General |
| Category: Inflammation/Rare Disease | ||||||
| 12/05/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.71 | General |
| Category: DIABETES | ||||||
| 12/03/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Education | In-kind items and services | $19.26 | General |
| Category: NEPHROLOGY | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $58.02 | General |
| 11/26/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $29.50 | General |
| Category: IMMUNOLOGY | ||||||
| 11/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $251.25 | General |
| Category: Cardio-renal | ||||||
| 11/23/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Travel and Lodging | In-kind items and services | $15.46 | General |
| Category: Cardio-renal | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $16.43 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $19.38 | General |
| Category: Nephrology | ||||||
| 11/14/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: DIABETES | ||||||
| 11/13/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $140.51 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $27.85 | General |
| Category: Nephrology | ||||||
| 11/12/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $26.74 | General |
| Category: Cardio-renal | ||||||
| 11/11/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $28.89 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/06/2024 | Ardelyx, Inc. | XPHOZAH 30 MG (Drug) | Food and Beverage | In-kind items and services | $122.88 | General |
| Category: NEPHROLOGY | ||||||
| 11/06/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/05/2024 | GENZYME CORPORATION | FABRAZYME (Biological) | Food and Beverage | In-kind items and services | $27.18 | General |
| Category: Genetic Disease | ||||||
| 11/04/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.08 | General |
| Category: Phosphate binder for ESRD | ||||||
| 10/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.20 | General |
| Category: Cardio-renal | ||||||
| 10/26/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,413.00 | General |
| Category: Cardio-renal | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 866 | 1,673 | $395,971 | $182,364 |
| 2022 | 15 | 941 | 1,976 | $443,653 | $226,504 |
| 2021 | 13 | 840 | 1,706 | $432,980 | $242,267 |
| 2020 | 15 | 1,027 | 2,164 | $540,860 | $268,871 |
Total Patients
3,674
Total Services
7,519
Medicare Billing
$920,006
Procedure Codes
55
All Medicare Procedures & Services
55 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 55 | 219 | $123,735 | $59,629 | 48.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 163 | 286 | $59,488 | $25,888 | 43.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 154 | 187 | $59,279 | $23,855 | 40.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 159 | 360 | $42,639 | $21,086 | 49.5% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 28 | 61 | $28,670 | $13,725 | 47.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 75 | 209 | $25,080 | $10,728 | 42.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 59 | 114 | $19,762 | $10,440 | 52.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 43 | 69 | $20,217 | $9,442 | 46.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $6,390 | $2,820 | 44.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 25 | 28 | $5,600 | $2,584 | 46.2% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 11 | 27 | $3,591 | $1,801 | 50.2% |
| 81000 | Manual urinalysis test with examination using microscope, non-automated | Office | 2023 | 76 | 95 | $1,520 | $367.12 | 24.2% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 49 | 261 | $130,500 | $71,634 | 54.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 166 | 189 | $57,516 | $28,262 | 49.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 161 | 283 | $47,908 | $25,835 | 53.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 183 | 450 | $49,936 | $24,672 | 49.4% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2022 | 11 | 93 | $46,500 | $21,547 | 46.3% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 34 | 67 | $30,150 | $13,764 | 45.7% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 74 | 222 | $26,640 | $12,413 | 46.6% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 69 | 143 | $22,661 | $11,463 | 50.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 27 | 39 | $8,739 | $5,193 | 59.4% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 28 | 39 | $6,162 | $3,792 | 61.5% |
| 90962 | Dialysis services, 1 physician visit per month (20 years or older) | Office | 2022 | 14 | 19 | $7,600 | $2,528 | 33.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 14 | 14 | $3,302 | $2,308 | 69.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $2,304 | $1,513 | 65.7% |
About Dr. Joseph Roglieri, D.O
Dr. Joseph Roglieri, D.O is a Nephrology healthcare provider based in Troy, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528021318.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Roglieri, D.O has received a total of $440,992 in payments from pharmaceutical and medical device companies, with $70,161 received in 2024. These payments were reported across 1,150 transactions from 46 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($318,077).
As a Medicare-enrolled provider, Roglieri has provided services to 3,674 Medicare beneficiaries, totaling 7,519 services with total Medicare billing of $920,006. Data is available for 4 years (2020–2023), covering 55 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Troy, NY
- Active Since 04/11/2006
- Last Updated 04/19/2012
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1528021318
Products in Payments
- ACTHAR (Biological) $137,664
- KRYSTEXXA (Biological) $82,599
- Kerendia (Drug) $60,693
- LOKELMA (Drug) $46,113
- FARXIGA (Drug) $32,930
- Auryxia (Drug) $22,942
- Veltassa (Drug) $22,791
- SAMSCA (Drug) $15,318
- KRYSTEXXA (Drug) $5,030
- AURYXIA (Drug) $4,295
- PURIFIED CORTROPHIN GEL (Drug) $1,069
- JYNARQUE (Drug) $1,047
- BENLYSTA (Biological) $500.48
- RAYALDEE (Drug) $443.48
- Velphoro (Drug) $324.40
- LUPKYNIS (Drug) $319.35
- NORTHERA (Drug) $276.32
- JESDUVROQ (Drug) $216.43
- TERLIVAZ (Drug) $214.21
- Rayaldee (Drug) $204.46
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Troy
Gampala Reddy, M.d, M.D
Nephrology — Payments: $3,793
Nephrology $3,793
Dr. Piti Ratanapanichkich, Md, MD
Nephrology — Payments: $2,204
Nephrology $2,204
Zoey Levine
Nephrology — Payments: $398.10
Nephrology $398.10
Sayed Ali, M.d, M.D
Nephrology — Payments: $387.66
Nephrology $387.66
Dr. Sundeep Dhillon, Md, MD
Nephrology — Payments: $329.58
Nephrology $329.58
Pooja Kayi, M.d, M.D
Nephrology — Payments: $97.16
Nephrology $97.16